Bortezomib in Treating Patients With Lymphoproliferative Disorders

You may be eligible if

• Histologically or cytologically confirmed lymphoproliferative disorder of 1 of the following subtypes:
• \* Relapsed or refractory grade I, II, or III follicular center cell lymphoma
• * Relapsed or refractory mantle cell lymphoma
• Measurable disease for non-Hodgkin's lymphoma (NHL) only
• * At least 1 unidimensionally measurable lesion
• * At least 2 cm by conventional techniques OR at least 1 cm by spiral CT scan
• * Lymph nodes no greater than 1 cm in short axis considered normal
• Absolute lymphocytosis greater than 5,000/mm\^3 with B-cell phenotype (CD19, 20,or 23 positive) with more than 30% bone marrow lymphocytes for CLL or other leukemic forms of NHL
• No known brain metastases
• Performance status - Karnofsky 70-100%
• At least 3 months
• See Disease Characteristics
• Absolute neutrophil count greater than 1,500/mm\^3 (500/mm\^3 if lymphomatous involvement of bone marrow)
• Platelet count greater than 50,000/mm\^3
• Bilirubin less than 1.5 times upper limit of normal (ULN)
• AST and ALT no greater than 2.5 times ULN (4 times ULN in case of liver metastases)
• Creatinine less than 1.5 times ULN
• No symptomatic congestive heart failure
• No New York Heart Association class III or IV heart disease
• No unstable angina pectoris
• No cardiac arrhythmia
• No myocardial infarction within the past 6 months
• No cerebrovascular accident or transient ischemic attack within the past 6 months
• No history of orthostatic hypotension
• No evidence of acute ischemia or significant conduction abnormality (left anterior hemiblock in the presence of right bundle branch block or second or third degree atrioventricular blocks) on electrocardiogram
• No uncontrolled hypertension requiring antihypertensive medication
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Febrile episodes up to 38.5°C allowed if no evidence of active infection
• No other uncontrolled concurrent illness
• No known or active HIV infection
• No ongoing or active infection
• No psychiatric illness or social situation that would preclude study entry
• At least 3 months since prior monoclonal antibody therapy (e.g., rituximab)
• No more than 3 prior regimens of conventional cytotoxic chemotherapy
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• At least 1 week since prior steroid therapy
• At least 4 weeks since prior radiotherapy and recovered
• At least 4 weeks since prior major surgery
• No other concurrent investigational agents